Lymphadenectomy in prostate cancer - Radio-guided lymph node mapping: An adequate staging method

Frontiers of Radiation Therapy and Oncology

Volumn 41, Issue , 2008, Pages 58-67

  Winter, A ^a   Wawroschek, F ^a  

^a KLINIKUM OLDENBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CONFERENCE PAPER; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METHODOLOGY; NOMOGRAM; PATHOLOGY; PROSTATE TUMOR; SENTINEL LYMPH NODE BIOPSY;

HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; NOMOGRAMS; PROSTATIC NEOPLASMS; SENTINEL LYMPH NODE BIOPSY;

EID: 49449085987     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000139879     Document Type: Conference Paper

References (26)

1. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F: EAU guidelines on prostate cancer. Eur Urol 2005;48:546-551.
2. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003;169(suppl 4):396.
3. Seitz M, Khoder W, Schlenker B, Gratzke C, Reich O, Stief C: Klinische Relevanz der 11C-Cholin PET/CT beim Prostatakarzinom. Urologe 2006;45(suppl 1):102.
4. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. J Urol 2001;58:843-848.
5. Weckermann D, Wawroschek F, Harzmann R: Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy? Eur Urol 2005;47:45-51.
6. Weingärtner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H: Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 1996;156:1969-1971.
7. Schuessler WW, Pharand D, Vancaille TG: Laparosopic standard pelvic node dissection for carcinoma of the prostate: is it accurate? Urology 1993;150:898-901.
8. Leitlinien zur Diagnostik von Prostatakarzinomen. Mitteilungen der DGU und des BDU. Urologe A 1999;38:388-401.
9. Winter A, Vogt C, Weckermann D, Harzmann R, Wawroschek F: Komplikationsraten verschiedener LA-Techniken beim klinisch lokalisierten Prostatakarzinom im Vergleich. Urologe 2005;44(suppl 1):79.
10. Heidenreich A, Varga Z, von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167:1681-1686.
11. Bader P, Burkhard FC, Markwalder R, Studer UE: Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514-518.
12. McDowell GC, Johnson JW, Tenney DM, Johnson DE: Pelvic lymphadenectomy for staging clinically localized prostate cancer: indications, complications, and results in 217 cases. Urology 1990;35:476-482.
13. Wawroschek F, Vogt H, Wengenmair, Hamm M, Keil M, Graf G, Heidenreich P, Harzmann R: Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer: technique and results of the first 350 cases. Urol Int 2003;70:303-310.
14. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R: Radioisotope-guided pelvic lymph node dissection for prostate cancer. J Urol 2001;166:1715-1719.
15. Goppelt M, Holl G, Wagner T, Harzmann R, Weckermann D: Sentinellymphadenectomy beim Prostatakarzinom: Erfahrungen nach über 1,000 Fällen. Urologe 2006;45(suppl 1):102-103.
16. Silva N Jr, Anselmi CE, Anselmi OE, Madke RR, Hunsche A, Souto JS, Souto CA, Sica FD, Pioner GT, Macalos EC, Hartmann AA, Lima MS: Use of gamma probe in sentinel lymph node biopsy in patients with prostate cancer. Nucl Med Commun 2005;26:1081-1086.
17. Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namika M: Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 2004;171:2268-2271.
18. 99MTC]diethylenetetramine pentaacetic acid-mannosyl-dextran. J Urol 2006;175:44-48.
19. Weckermann D, Hamm M, Dorn R, Wagner T, Wawroschek F, Harzmann R: Sentinel lymph node dissection in prostate cancer: experience after more than 800 interventions. Urologe 2006;45:723-727.
20. Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Märkl B, Gordijn R, Harzmann R: The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 2003;43:132-137.
21. Haas J, Wagner T, Wawroschek F, Arnold H: Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients. Pathol Res Pract 2005;200:763-770.
22. Catalona WJ, Miller DR, Kavoussi LR: Intermediate-term survival results in clinically understated prostate cancer patients following radical prostatectomy. J Urol 1988;140:540-543.
23. Bader P, Burkhard FC, Markwalder R, Studer UE: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849-854.
24. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252-2255.
25. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R: Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ≤ 10 ng/ml and biopsy Gleason score of ≤ 6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int. 2006;97:1173-1178.
26. Ganswindt U, Paulsen F, Corvin S, Eichhorn K, Glocker S, Hundt I, Birkner M, Alber M, Anastasiadis A, Stenzl A, Bares R, Budach W, Bamberg M, Belka C: Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer 2005;5:91.